Clinical trial
Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients
NCT00458978 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- July 31, 2014
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent laryngeal verrucous carcinoma, recurrent lip and oral cavity squamous cell carcinoma, recurrent metastatic squamous cell carcinoma in the neck with occult primary, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharyngeal keratinizing squamous cell carcinoma, recurrent oral cavity verrucous carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent salivary gland carcinoma, salivary gland squamous cell carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage iv hypopharyngeal squamous cell carcinoma, stage iv laryngeal squamous cell carcinoma, stage iv laryngeal verrucous carcinoma, stage iv lip and oral cavity squamous cell carcinoma, stage iv major salivary gland carcinoma, stage iv nasal cavity and paranasal sinus squamous cell carcinoma, stage iv nasopharyngeal keratinizing squamous cell carcinoma, stage iv oral cavity verrucous carcinoma, stage iv oropharyngeal squamous cell carcinoma, tongue carcinoma, untreated metastatic squamous cell carcinoma to neck with occult primary